Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.46 |
| ▸ | CES2 | O00748 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL885016 | 0.81 | CA12 (0.62) | FNTAFNTBHPGDCA12CA1 | |
| SCHEMBL7300892 | 0.79 | CES1 (0.52) | CES1CES2HPGDCA12CA1 | |
| SCHEMBL7300898 | 0.79 | CES1 (0.55) | CES1CES2HPGDGAAKDM4E | |
| SCHEMBL12018336 | 0.78 | CES1 (0.56) | CES1CES2HPGDGAAKDM4E | |
| SCHEMBL9473526 | 0.76 | EGFR (0.46) | CES1CES2HPGDGAAMEN1 | |
| SCHEMBL24209232 | 0.75 | CA12 (0.59) | FNTAFNTBHPGDCA12CA1 | |
| SCHEMBL28791135 | 0.75 | CES1 (0.52) | CES1CES2HPGDGAAKDM4E | |
| SCHEMBL11583619 | 0.75 | HDAC1 (0.53) | CES1CES2HPGDGAAKDM4E | |
| SCHEMBL8657972 | 0.75 | CES1 (0.52) | CES1CES2HPGDGAAKDM4E | |
| SCHEMBL3560675 | 0.74 | KMT2A (0.67) | MAOAMAOBFNTAFNTBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101636390-B | Napadisylate salt of a muscarinic M3 antagonist | ARGENTA DISCOVERY LTD GB | 2013-06-12 | — | — | CN | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| CN-101678005-B | Combination of a muscarinic receptor antagonist and a beta-2 adrenergic receptor agonist | ARGENTA DISCOVERY LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-101282949-B | Azole and thiazole derivatives and uses thereof | ARGENTA DISCOVERY LTD | 2012-05-23 | — | — | CN | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096136-A1 | COMBINATIONS WITH A MUSCARINIC RECEPTOR ANTAGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096128-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES 2 | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008017827-A2 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
| CN-1038410-C | Butynelamine derivative | NIPPON SHINYAKU CO LTD (JP) | 1998-05-20 | — | — | CN | disclosed |
| US-5036098-A | Urogenital disorders | NIPPON SHINYAKU CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | CES1 1426/4885CES2 2828/4885MAOA 3002/4885 |
| US-20110046191-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CES1 2240/4885CES2 2679/4885MAOA 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.